APP and early-onset autosomal dominant Alzheimer disease: Because of its multiple therapeutic benefits, synthetic retinoid tamibarotene (Am80) is being explored intensively as a possible medication for Alzheimer’s disease which tends to reduce the level of insoluble Aß42 in APP23 AD model mice, according (Kawahara et al., 2009) As such acitretin is under investigation, that has been shown to raise the levels of the α-secretase of amyloid-protein precursor (APP), promoting the non-amyloidogenic process in neuroblastoma cells and lowering Aß levels in APP/PS-1 AD model (Tippmann et al., 2009).